Presbyopia

According to the company, a $68 million Series D financing is co-led by Arboretum Ventures and Johnson & Johnson Innovation – JJDC Inc. It also has secured $15 million in structured capital from Catalio Capital Management, with $10 million drawn at closing.

The trial is evaluating phentolamine ophthalmic solution 0.75% for the treatment of presbyopia.

Explore cutting-edge ophthalmology innovations in this new series on the Ophthalmology Times EyePod podcast. Throughout this series, we'll hear insights from various stakeholders in clinical practice, academia, and industry. In this episode, host Ehsan Sadri, MD, engages in a conversation with Jeffry Weinhuff, managing partner at Visionary Ventures, exploring trends and offering advice for individuals driven by an entrepreneurial mindset.

Infuse Multifocal silicone hydrogel (SiHy) daily disposable contact lenses leverage Bausch + Lomb’s proprietary lens tech to deliver all-day comfort and seamless transitions between near, intermediate, and distance vision for patients with presbyopia.

Preeya Gupta, MD, reported results of the trials at the American Society of Cataract and Refractive Surgery annual meeting in San Diego, showed that CSF-1, a low dose pilocarpine with an optimized formulation, demonstrated significant 2-line improvement from baseline.

Allergan developed VUITY, which it noted is the first and only FDA-approved eye drop to treat presbyopia. The FDA has now approved a two-dose option.

Ehsan Sadri, MD, FACS, and William Trattler, MD, highlight some of the pending FDA approvals and PDUFA dates in the anterior segment sector and what these products will mean for ophthalmologists and their patients.

BRIO-I is a double-masked, randomized, multi-center, safety and efficacy study that enrolled emmetropic phakic and pseudophakic presbyopic subjects.

According to the company, the investigational, novel eye drop candidate was assigned a PDUFA goal date of October 22, 2023.

According to Lento Bio, its collaboration with FSU will focus on medicinal chemistry and will help accelerate lead asset development, with board expansion focused on well-rounded scientific expertise.

According to the company, the launch of the presbyopia phase 3 program is supported by positive clinical results that demonstrated durable efficacy and a favorable safety profile.

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

Investigators test the efficacy of phentolamine alone and with low-dose pilocarpine.

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Jay Pepose, MD, PhD. presented Incorporating "Topical Therapy in the Treatment of Presbyopia" at EyeCon 2022 in Marco Island, Florida.

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

The deal with FamyGem Life Sciences covers the development and commercialization of Nyxol eye drops for the reversal of mydriasis, presbyopia and night vision issues.

The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.

The company noted the phase 3 study looked at MicroLine as a potential on-demand treatment for presbyopia.

LENZ Therapeutics has unveiled positive topline data from its INSIGHT study achieved by 2 formulations to treat presbyopia.

The IOL has a hybrid design that combines the benefits of central extended depth-of-focus technology and multifocal technology that provides a continuous range of high-quality vision ranging from distance and intermediate and near vision to about 12 to 14 inches.

The Grail study finds the device can offer positive outcomes for patients.